Marlboro Medical Device Co. Attributes $700M Growth To Tax Reform

MARLBOROUGH, MA—A Marlborough medical device company is attributing, partly, its $701.1 million increase in revenue for its latest fiscal quarter to the new federal tax laws.

Holigic released its financial results for the fiscal first quarter ending Dec. 30, 2017, which showed the the increase, which amounts to 7.7 percent compared to the same period the prior year.

Excluding the acquired medical aesthetics and divested blood screening businesses, revenue increased 2.7 percent. The company said its revenue growth rates in the first quarter were negatively impacted by four extra selling days in the year prior.

"We are pleased with our first quarter results," said Steve MacMillan, Hologic's chairman, president and chief executive officer, in a statement. "We posted solid revenue just above our guidance range, driven by strength in our breast health, molecular diagnostics and international businesses. In addition, U.S. tax reform is helping us increase our earnings guidance for the year, while simultaneously re-investing in the business to drive future growth."

Photo via Shutterstock